Novavax (NVAX) received a Buy rating from Piper Jaffray analyst Edward Tenthoff today. The company’s shares closed on Friday at $1.72.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of 7.3% and a 38.9% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Alpine Immune Sciences Inc, and Eiger Biopharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novavax with a $6 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.75 and a one-year low of $1.05. Currently, Novavax has an average volume of 6.17M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza, and Ebola virus.
